Changing strategies for target therapy in gastric cancer - sprookjes - yvandenbroek - TriplyDB

Changing strategies for target therapy in gastric cancer

Changing strategies for target therapy in gastric cancer

http://www.wikidata.org/entity/Q26774513

about

Molecular and functional evaluation of a novel HIF inhibitor, benzopyranyl 1,2,3-triazole compound.DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway Recombinant human bone morphogenetic protein-2 inhibits gastric cancer cell proliferation by inactivating Wnt signaling pathway via c-Myc with aurora kinases.Expression and function of transforming growth factor‑β‑activated protein kinase 1 in gastric cancer.Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine.CXCR7 as a chemokine receptor for SDF-1 promotes gastric cancer progression via MAPK pathways.Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer.KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.

P2860

Q36229899-AE9D93F8-B881-4B4C-BE06-0F87ECB137B0 Q37652251-E9DD3ED1-4931-44ED-81FA-4369B383E4C4 Q37687413-99C60EE5-861B-4F66-9F31-18B146DF57A9 Q38656687-30279026-B690-4B81-BFD3-A4A72A43B8D3 Q42332601-2ABBFDA7-F409-457C-A3E3-A72B6651922D Q51102743-AEC1B749-B473-4368-801F-48E4D890E454 Q55313144-3C864E4E-68CF-4A73-AB6E-84640A7089FC Q55513229-603D59D8-B266-45C0-9574-02C4B9755858

P2860

Changing strategies for target therapy in gastric cancer

http://www.wikidata.org/entity/Q26774513

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Changing strategies for target therapy in gastric cancer

@ast

Changing strategies for target therapy in gastric cancer

@en

Changing strategies for target therapy in gastric cancer

@nl

type

label

Changing strategies for target therapy in gastric cancer

@ast

Changing strategies for target therapy in gastric cancer

@en

Changing strategies for target therapy in gastric cancer

@nl

prefLabel

Changing strategies for target therapy in gastric cancer

@ast

Changing strategies for target therapy in gastric cancer

@en

Changing strategies for target therapy in gastric cancer

@nl

P1433

Q26774513-17016ECA-DDBF-4C7F-8617-64B392B72FAD

P1476

Q26774513-447C46F0-2F4A-4E9F-8BE3-09030AE26C61

P2093

Q26774513-8F1DBBEC-F321-461A-B37E-4A202FA81FE9

Q26774513-BD60B343-6109-4E17-A88E-7BA52539D6ED

P2860

Q26774513-01EA4214-9EE8-4610-B203-2C3DF1E1BCC1

Q26774513-03C2B5E8-2842-44CD-BBB3-940F7516F699

Q26774513-042A3ADE-8831-494A-8B39-5AC80EE03101

Q26774513-07A46F6E-5159-4A0C-B921-91CB5EF6D3D0

Q26774513-0A130BC9-6C41-432B-BBAA-A18A0D51F5AA

Q26774513-0B1B15A4-80BF-4926-966A-3DBCAAAF4B3A

Q26774513-133E80BC-52DA-4C95-919A-E04CA7A2E994

Q26774513-138AE4DD-9C92-4024-8170-00CF8313EDB7

Q26774513-147C5FDA-5BB7-4C34-8530-EA3F803EF2E0

Q26774513-17F13607-19A0-4060-A96B-17EE5BBFFEC5

P304

Q26774513-208AA3BD-4CA4-4399-894B-38B6D6AF0A64

P31

Q26774513-05ABC919-B31B-435A-B7C2-0718B9E65876

P356

Q26774513-3DB7DEEC-B5E9-42F5-8D63-818ECF5DD77C

P407

Q26774513-5419EB65-1CF9-4012-9DA7-43EB08E60573

P433

Q26774513-2E395485-D79E-4CBC-A68D-B83BE04EA858

P478

Q26774513-8AFC5116-B707-49D7-A6E5-473E55CED4B4

P577

Q26774513-82B6EE76-9072-4450-A26A-7C7A7051E0DF

P5875

Q26774513-3D39CCF7-1FF5-4FF7-80C2-F1A12C1ED02F

P698

Q26774513-8E399A47-3441-4E9C-AE74-2028169DB3F5

P932

Q26774513-C78014B4-956A-4F3F-8AB4-A59937AB1B9E

P356

WJG.V22.I3.1179

P1433

World Journal of Gastroenterology

P1476

Changing strategies for target therapy in gastric cancer

@en

P2093

Sang Cheul Oh

http://www.w3.org/2001/XMLSchema#string

Suk-Young Lee

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy for advanced gastric cancer

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche

Immunotherapy in gastric cancer

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

P304

1179-89

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V22.I3.1179

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

290625469

http://www.w3.org/2001/XMLSchema#string

P698

26811656

http://www.w3.org/2001/XMLSchema#string

P932

4716029

http://www.w3.org/2001/XMLSchema#string